Category: Uncategorized

Once upon a time there was a guy called Ethan, and he loved to write.
  • Shift Work and Metabolic Health: The Silent Risk Millions of UK Workers Are Largely Unaware Of

    Shift Work and Metabolic Health: The Silent Risk Millions of UK Workers Are Largely Unaware Of

    Around 3.5 million people in the UK work shifts, according to the Office for National Statistics. That covers NHS nurses working nights, warehouse staff on rotating rotas, lorry drivers, hotel and restaurant workers, and a significant chunk of emergency services. Most of them are aware that shift work is tiring. Fewer are aware that it is doing measurable damage to their metabolic health, sometimes long before any symptom appears.

    NHS nurse on night shift, illustrating shift work metabolic health risks for healthcare workers
    Photo by Daniil Kondrashin on Pexels

    I’ve spent some time looking at what the circadian biology research actually says here, because the gap between the science and public awareness is striking. This is not a case of vague risk; the mechanisms are reasonably well understood, and they play out in ways that affect insulin sensitivity, cardiovascular risk, and even cancer incidence. The workers bearing the largest burden are disproportionately in lower-paid roles with the least flexibility to change their schedules.

    What shift work does to your body clock

    Human physiology is built around a roughly 24-hour cycle, governed by the suprachiasmatic nucleus in the hypothalamus and synchronised primarily by light. When you eat, sleep, and wake at irregular times, that internal clock and the external environment fall out of step. Researchers call this circadian misalignment, and its downstream effects are not trivial.

    Insulin sensitivity drops meaningfully during biological night. A 2019 study published in Science Advances by researchers at the Brigham and Women’s Hospital found that people in a simulated night-shift schedule showed a 17% reduction in insulin sensitivity within days. The pancreas partially compensates, but not always fully, and over years of shift work the cumulative exposure appears to push people towards type 2 diabetes at a notably higher rate than day workers. A meta-analysis in Occupational and Environmental Medicine put the elevated risk for shift workers at approximately 9% higher than those working standard hours, with rotating shifts carrying more risk than fixed nights.

    The cardiovascular picture is similarly concerning. Cortisol and inflammatory markers behave differently when sleep is displaced. A review in the European Heart Journal found shift workers have a roughly 23% higher risk of myocardial infarction compared to non-shift workers. Blood pressure regulation is also disrupted; the normal nocturnal dip in blood pressure, which is protective, does not occur reliably in people sleeping during the day.

    The cancer link is real, though nuanced

    Since 2007, the International Agency for Research on Cancer has classified night shift work as a probable human carcinogen (Group 2A). The biological mechanism centres on melatonin suppression. Melatonin, produced by the pineal gland in darkness, has anti-tumour properties. When artificial light suppresses it during a night shift, that protective output is reduced. Breast cancer is the most studied outcome, with several large cohort studies finding modestly elevated risk in women doing long-term night work, though effect sizes vary and the epidemiology is complicated by lifestyle factors.

    The evidence is strong enough that the WHO and the NHS recognise night shift work as an occupational exposure. What is less clear is the exact dose-response relationship, i.e., how many years of shift work, how many nights per week, and what kind of light exposure tips someone into meaningfully elevated risk. The honest answer is that researchers are still working this out.

    Warehouse worker on night shift, representing the shift work metabolic health risks in UK logistics
    Photo by IAN on Pexels

    Who in the UK is most exposed

    NHS data from NHS England suggests roughly 350,000 nurses work some form of night or rotating shift. The logistics sector, expanded significantly since 2020, employs hundreds of thousands of warehouse and distribution workers on 24-hour rota patterns. Hospitality workers on late and split shifts face a different but related problem: irregular sleeping windows, high caffeine intake, and compressed recovery time between shifts.

    What links these groups is that most cannot choose their hours, and many are not given adequate information about the health implications. If you spend time looking at what research says about sedentary office work and cardiovascular risk, you quickly notice that desk workers at least have some agency over their movement patterns. Shift workers often have less.

    There is also an inequality dimension. Night and rotating shift work is more common in ethnic minority communities in the UK, partly due to sector concentration in healthcare, logistics, and manufacturing. Since cardiovascular risk and type 2 diabetes already have elevated prevalence in some of these communities, circadian disruption can compound an existing burden.

    What mitigation actually looks like

    I want to be clear that there is no perfect solution here short of ending shift work, which is obviously not realistic. But the evidence does point to some practical levers worth taking seriously.

    Light exposure matters more than most workers know. Getting bright light during the first half of a night shift and then minimising light exposure during the commute home (blue-light-blocking glasses genuinely help here, despite how they look) can reduce circadian disruption. Blackout curtains for daytime sleep are not optional; they are a genuine physiological intervention.

    Meal timing is underrated. Eating during biological night amplifies insulin resistance. Workers who can shift their main caloric intake to biological day hours, even imperfectly, appear to have better metabolic outcomes. This is not about dieting; it is about when food lands relative to your body clock. If you are looking at evidence on time-restricted eating, the research on how meal timing affects weight and metabolic markers is directly relevant here.

    Rotating shifts vs. fixed nights. The evidence consistently shows that fixed night shifts, while socially disruptive, produce less metabolic damage than rotating patterns. The body can achieve a degree of adaptation to a fixed schedule; it cannot adapt to one that keeps changing. Where employers have the flexibility to offer fixed patterns, there is a reasonable case for doing so on health grounds.

    Caffeine management. Many shift workers use caffeine heavily to manage alertness, which is understandable. But consuming it in the second half of a shift significantly worsens daytime sleep quality. The research on caffeine dependence and its clinical significance applies with particular force to people already fighting a compromised sleep window.

    Some NHS trusts are beginning to build structured health checks specifically for long-term shift workers into occupational health programmes, including HbA1c testing and blood pressure monitoring more frequently than for day workers. That is the right direction. Tools that help workers and their employers manage scheduling and health data more intelligently, from workforce planning software to health-monitoring integrations, are part of how this problem gets addressed at scale; dijitul.ai is one example of how AI-assisted administration tools are starting to appear in operational contexts like this.

    The policy gap

    The UK has a Working Time Regulations framework that caps hours and mandates rest periods, but it does not specifically address circadian health. There is no requirement for employers to inform workers of the biological risks of long-term night work, and occupational health access is patchy, particularly in logistics and hospitality where smaller employers dominate.

    Given what we now know about shift work metabolic health outcomes, the case for updated guidance from NICE and more systematic screening in at-risk occupational groups is strong. A worker who has done 15 years of rotating night shifts is not in the same cardiovascular risk category as a day worker of equivalent age and BMI. The clinical framework should reflect that.

    Millions of UK workers are doing essential work under conditions that quietly increase their risk of diabetes, heart disease, and potentially cancer. That is worth knowing about clearly, not buried in occupational health small print.

    Frequently Asked Questions

    How does shift work affect insulin sensitivity?

    Circadian misalignment caused by working at night disrupts the body’s normal insulin response cycle. Research shows that insulin sensitivity can drop significantly within days of night-shift schedules, and long-term rotating shift work is associated with around a 9% higher risk of developing type 2 diabetes compared to standard day workers.

    Is night shift work linked to cancer?

    The International Agency for Research on Cancer classifies night shift work as a probable human carcinogen (Group 2A). The main proposed mechanism is suppression of melatonin, which has anti-tumour properties, during exposure to artificial light at night. Breast cancer is the most studied outcome, with modest elevated risk found in women doing long-term night work across several large cohort studies.

    Which UK workers are most at risk from shift work metabolic health problems?

    NHS nurses, logistics and warehouse workers, hospitality staff, and emergency services personnel make up the majority of the UK’s estimated 3.5 million shift workers. Rotating shift patterns carry more metabolic risk than fixed night schedules, and workers with limited schedule flexibility face the greatest cumulative exposure.

  • AI Self-Diagnosis in the UK: What Happens When Patients Use Chatbots to Interpret Their Symptoms

    AI Self-Diagnosis in the UK: What Happens When Patients Use Chatbots to Interpret Their Symptoms

    Something has quietly shifted in how people in the UK engage with their health before they ever book a GP appointment. Rather than reaching for NHS 111 or typing symptoms into a search engine, a growing number of patients are having full-length, back-and-forth conversations with large language models, asking things like “could this be lupus?” or “should I be worried about this lump?” The results of those conversations are shaping what people believe, how urgently they act, and in some cases, what they tell their doctors when they eventually do get a consultation.

    AI self-diagnosis in the UK is not a fringe behaviour any more. A 2024 survey by the Nuffield Trust found that digital health tools, including AI-driven ones, were being used by patients in ways that outpaced any formal guidance on appropriate use. The question worth asking plainly is: how accurate is AI when it comes to interpreting human symptoms, and who is responsible when it gets it wrong?

    Woman using a smartphone to look up symptoms, illustrating AI self-diagnosis UK behaviour
    Photo by Laura James on Pexels

    What the research actually shows about chatbot diagnostic accuracy

    The headline findings on accuracy are mixed, and I’d argue the nuances matter more than the averages. A 2023 study published in JAMA Internal Medicine found that ChatGPT performed reasonably well on standardised clinical vignettes, ranking the correct diagnosis in its top three suggestions around 72% of the time. Sounds reassuring until you consider what the other 28% of cases looked like, and that real patients presenting to chatbots rarely match the clean framing of a clinical vignette.

    The more concerning pattern is directional confidence. Large language models, by design, generate fluent, authoritative-sounding text. A patient asking about chest tightness and fatigue might receive a response that confidently prioritises anxiety or acid reflux, without adequately surfacing the possibility of cardiac involvement. The model is not lying. It is doing exactly what it was trained to do: produce plausible, coherent output weighted by probability. But medicine is full of low-probability, high-consequence events that probability-weighted systems systematically underweigh.

    Research from University College London published in early 2025 looked specifically at patients who had used AI tools to interpret symptoms before a GP visit. Around 34% had formed a strong prior belief about their diagnosis before the consultation, and GPs reported that challenging those beliefs added meaningful time pressure to already stretched appointments. This is a practical problem with systemic consequences.

    Why certain symptom types carry higher risk

    Not all AI symptom checking carries equal risk. For common, self-limiting conditions, a chatbot telling someone they likely have a cold or mild gastroenteritis is probably harmless, and might even reduce unnecessary demand on NHS services. The risk concentrates in two areas.

    First, rare or atypical presentations of serious conditions. Symptoms of conditions like ME/CFS are notoriously diffuse and overlap with dozens of other diagnoses. An AI trained predominantly on mainstream clinical literature may push patients toward more common explanations and away from the right one. Second, mental health presentations. A patient describing low mood, cognitive fog, and fatigue might be told by a model that they sound stressed or sleep-deprived, when what they are experiencing is a prodrome of something requiring clinical assessment.

    GP consultation desk representing the clinical encounter following AI self-diagnosis in the UK
    Photo by Thirdman on Pexels

    There is also a particular problem with supplement and lifestyle recommendations that chatbots often attach to their diagnostic suggestions. A patient convinced they have a magnesium deficiency based on an AI conversation might spend weeks self-treating before discovering the real cause of their symptoms. The information itself is not necessarily wrong; the sequencing and framing almost always is.

    Where UK regulation currently stands

    This is where things get genuinely complicated. The MHRA’s updated framework for software as a medical device, which I’ve covered in the context of AI-driven health apps, applies to tools that are intended to be used for a medical purpose. The word “intended” is doing enormous work here. A general-purpose large language model, such as ChatGPT or Google’s Gemini, is not marketed as a diagnostic tool. Its developers explicitly disclaim medical use. That puts it largely outside the MHRA’s current regulatory perimeter, even when patients are using it for exactly that purpose.

    The Care Quality Commission, which regulates health services in England, has similarly limited reach here. CQC oversight applies to registered providers. A software product that refuses to call itself a health service sits in a gap that existing frameworks were never designed to address. The CQC’s 2025 annual report on innovation in health acknowledged the issue without offering a concrete regulatory pathway.

    NHS England has issued informal guidance encouraging patients to use NHS 111 or the NHS App as first points of contact for health concerns, and to treat AI chatbots as general information tools rather than diagnostic ones. That guidance is reasonable. The gap between reasonable guidance and actual patient behaviour is, as usual, wide. You can find the NHS’s current position on digital health tools at nhs.uk.

    What this means for patients navigating it now

    I’d be dishonest if I said AI chatbots have no value in a health context. They can help patients organise and articulate symptoms more clearly before an appointment. They can provide useful background on how a diagnosis works, what questions to ask a GP, or what a prescribed medication does. Used in that framing, as a preparation tool rather than a diagnostic oracle, they are genuinely useful.

    The problem is that the interface encourages a different behaviour. Asking a chatbot “what is causing my headaches?” and receiving a structured, confident three-paragraph response does not feel like reading a general information article. It feels like receiving a personalised assessment. That experiential difference matters, because it shapes how strongly a person holds the belief that follows.

    My honest take: treat any chatbot response about personal symptoms the same way you’d treat advice from a well-read friend with no medical training. Useful context, possibly, but not a clinical opinion. If you are researching health information online more broadly and want better tools for evaluating what comes up in search results, resources like expert free SEO tools can at least help you understand which sources rank highly and why, though that is a separate skill from evaluating medical credibility.

    The harder structural question

    Underneath the accuracy debate is a more uncomfortable truth: patients in the UK are turning to AI in part because accessing a GP in 2026 is genuinely difficult. NHS England data shows average waiting times for a routine GP appointment still exceeding two weeks in many areas. When someone is worried and can’t get timely access to a clinician, a chatbot that responds immediately feels better than nothing. That is not a technology failure. That is a capacity failure that technology is filling imperfectly.

    Regulatory frameworks that treat AI symptom use as purely a tech problem to be policed will miss this. The more productive frame is: how do we design AI health tools that are accurate about their own limitations, that actively route patients toward appropriate care rather than substituting for it, and that work within NHS pathways rather than around them? That design challenge is solvable. The regulatory appetite to mandate it is still catching up.

  • The MHRA’s New Approach to AI Medical Devices: What It Means for the Apps Diagnosing and Monitoring You

    The MHRA’s New Approach to AI Medical Devices: What It Means for the Apps Diagnosing and Monitoring You

    If you have ever used an app to log symptoms, interpret a blood glucose reading, or get a personalised health recommendation, there is a real chance you have interacted with something that the MHRA considers a medical device. Most people have no idea that category exists, let alone what it requires of the companies building these tools. The MHRA AI medical device regulation UK framework is one of the most consequential and least-discussed shifts in British healthcare right now, and it is worth understanding in plain terms.

    NHS clinician reviewing a health app on a tablet, relevant to MHRA AI medical device regulation UK
    Photo by Tima Miroshnichenko on Pexels

    What the MHRA actually classifies as a medical device in software

    The MHRA’s Software and AI as a Medical Device (SaMD) framework draws a clear line: if a piece of software is intended to be used for a medical purpose, it falls under regulatory oversight. That includes diagnosing a condition, predicting deterioration, monitoring a chronic illness, or informing a treatment decision. General wellness apps, step counters, and sleep trackers that make no medical claims sit outside this definition. The moment an app says it can detect an arrhythmia, flag early signs of diabetic retinopathy, or suggest a medication adjustment, it crosses the line.

    The MHRA uses a risk-based classification system, running from Class I (lowest risk) up to Class III (highest risk). Most AI-driven diagnostic tools land in Class IIa or IIb, which requires a Conformity Assessment carried out by a UK Approved Body. Developers must maintain a technical file that includes clinical evidence, details of the algorithm’s training data, and a post-market surveillance plan. For Class IIb and above, that plan must be proactive, not reactive. The MHRA’s published guidance on AI as a medical device lays out the current framework in detail, including the 2024 roadmap updates that are now being implemented.

    How the UK framework differs from what came before

    Prior to the UK leaving the EU’s regulatory orbit, software developers could rely on CE marking under the EU MDR. Since then, the MHRA has been building its own regime, and the UK Conformity Assessed (UKCA) mark is now the requirement for Great Britain. The MHRA published its “Software and AI as a Medical Device Change Programme” in stages from 2022 onwards, and the 2026 position is that manufacturers must demonstrate what the regulator calls “safe and effective performance” throughout the entire product lifecycle, not just at launch.

    What makes this genuinely different for AI tools is the acknowledgement of continuous learning. An algorithm that updates itself based on new patient data is not the same product it was six months ago. The MHRA’s framework addresses this with the concept of predetermined change control plans, meaning developers must specify in advance what kinds of changes they anticipate the model making and get those parameters approved. That is a meaningful shift from how software regulation has historically worked, where a product was reviewed once and then largely left alone.

    What developers are required to demonstrate

    In practical terms, a company seeking approval for an AI-driven diagnostic app needs to show several things. Clinical validation is the big one. The algorithm must be tested against the population it will actually serve, not just the dataset it was trained on. This matters enormously because training data bias is a real and documented problem. An ECG algorithm trained predominantly on data from white men in their forties will perform differently on South Asian women in their sixties, and the MHRA expects developers to account for that explicitly.

    Beyond clinical evidence, developers must provide transparency about how the algorithm reaches its outputs. That does not necessarily mean publishing the model weights, but it does mean producing documentation that allows a clinician to understand the basis for a recommendation. There is also a usability requirement: the interface must be tested with real users to ensure the information is presented in a way that supports safe decision-making rather than creating confusion or misplaced confidence.

    Post-market surveillance is where many smaller developers struggle. They are required to collect real-world performance data after launch, track adverse events, and submit periodic safety update reports. For a well-funded medtech company this is manageable. For a startup with a lean team, the administrative burden is substantial, and I would argue that is partly why so many health apps quietly drop medical claims from their marketing to avoid classification altogether.

    Where the gaps still are

    The framework is improving, but several gaps remain. Enforcement is the most obvious. The MHRA does not have the resource to proactively audit every app marketed to UK users. In practice, most enforcement is complaint-driven, which means a poorly validated tool can operate for months or years before anyone formally challenges it. This is particularly concerning given how many AI-driven health apps are marketed directly to consumers via app stores, where the App Store and Google Play review processes have no meaningful medical device checkpoint.

    International products are another complexity. An app developed in the US, Canada, or elsewhere, marketed to UK users, technically requires UKCA marking if it makes medical claims. In reality, many do not have it, and the MHRA’s ability to pursue overseas developers is limited. Given the rapid growth of AI wearables and monitoring platforms, this is not a small edge case.

    There is also a definitional grey area around generative AI tools used in health contexts. A large language model that answers questions about symptoms is almost certainly providing information, not diagnosis, and therefore sits outside SaMD classification. But that line is blurring. If a tool consistently recommends specific courses of action based on symptom inputs, at what point does it become a diagnostic aid? The MHRA has signalled it is watching this space closely, but firm guidance is still in progress.

    What this means if you use health apps

    As a consumer, you have limited visibility into whether a given app has gone through proper regulatory review. A few practical checks help. If an app makes medical claims, look for a UKCA mark or CE mark in the product documentation (many legitimate medical device apps display this in their terms or in app store listings). Check whether the company publishes a clinical evidence summary. If they do not, ask yourself why. Apps that have genuinely validated their algorithms tend to say so clearly because it is a genuine competitive advantage.

    The MHRA maintains a register of certified medical devices, though navigating it is not exactly user-friendly. It is worth knowing that the NHS App and NHS-commissioned digital tools are held to a higher standard, going through NHS England’s Digital Technology Assessment Criteria (DTAC) as well as MHRA requirements. That dual-layer review gives NHS-approved tools more credibility than consumer apps operating solely on the basis of self-declaration.

    The regulatory picture for AI in health is improving, but slowly. The gap between what technology can claim and what it has rigorously demonstrated is still wide in places. For anyone relying on an app to inform decisions about their health, that gap is worth keeping front of mind.

    If you are thinking about how digital health tools intersect with NHS systems and patient data, the questions raised about NHS diagnostic pathways and patient experience are closely connected. And the broader question of how UK adults manage their health with limited NHS access is part of why so many people turn to consumer apps in the first place. Understanding what those apps are, and are not, legally required to prove is a reasonable starting point for anyone trying to make informed choices.

  • Seed Oils, Inflammation and the British Diet: Separating the Science from the Culture War

    Seed Oils, Inflammation and the British Diet: Separating the Science from the Culture War

    If you spend any time in British health and wellness spaces online, you have probably encountered the seed oil debate. On one side, influencers warn that vegetable oils are quietly destroying your gut lining, triggering systemic inflammation and driving chronic disease. On the other side, the instinct is to dismiss all of that as paranoid nonsense from people who eat too much red meat and distrust mainstream medicine. I think both camps are getting it wrong, and the actual evidence is more interesting than either side admits.

    Various cooking oils on a kitchen counter, relevant to the seed oils inflammation UK debate
    Photo by Андрей on Pexels

    What are seed oils, and how much do UK adults actually consume?

    The term “seed oils” covers refined oils extracted from seeds rather than fruit or animal tissue: sunflower, rapeseed, corn, soybean, safflower and cottonseed oils are the ones usually named. In practice, rapeseed oil is by far the most common in the UK, used heavily in food manufacturing and sold widely as “vegetable oil”. Sunflower oil is the second most visible on supermarket shelves.

    According to the National Diet and Nutrition Survey (NDNS), UK adults consume a significant proportion of their fat intake from vegetable oils and spreads. The key point for any honest discussion is that these oils are not a fringe ingredient; they are embedded in the processed food supply. Ready meals, crisps, biscuits, takeaway food and most manufactured sauces contain them. So if you are eating an average British diet, you are consuming seed oils in meaningful quantities whether you think about it or not.

    The linoleic acid argument: is there anything to it?

    The core claim from seed oil sceptics centres on linoleic acid, an omega-6 polyunsaturated fatty acid (PUFA) that makes up a large share of most seed oils. The argument runs like this: linoleic acid is metabolised into arachidonic acid, which is itself a precursor to pro-inflammatory signalling molecules called eicosanoids. Higher linoleic acid intake therefore equals more inflammation. It sounds mechanistically plausible, and that is exactly why it has traction.

    The problem is that the leap from metabolic pathway to clinical outcome is where the evidence does not hold up cleanly. A 2020 systematic review published in Circulation examined randomised controlled trials and found that replacing saturated fat with linoleic-acid-rich oils reduced cardiovascular events. A 2021 meta-analysis in the British Journal of Nutrition found no consistent evidence that higher linoleic acid intake raises circulating arachidonic acid or inflammatory markers in humans to a clinically significant degree. The body appears to regulate this conversion tightly under normal dietary conditions.

    I am not saying those findings close the debate entirely. The quality of available trials is variable, follow-up periods differ, and some researchers make a credible case that the omega-6 to omega-3 ratio matters more than absolute linoleic acid intake. But “plausible mechanism” is not the same as “demonstrated harm”, and that distinction matters enormously. You can find the same pattern in a lot of nutrition debates, including the one around fibre intake in the UK, where mechanistic logic and real-world outcomes sometimes point in different directions.

    What does NICE guidance actually say about dietary fats?

    NICE does not single out seed oils for restriction. The current lipid guidance (CG181, updated most recently in 2023) recommends reducing saturated fat intake and suggests that replacing saturated fats with unsaturated fats, including PUFAs, is associated with better cardiovascular outcomes. That is broadly consistent with the position of the British Heart Foundation and the British Dietetic Association.

    NICE does acknowledge that dietary fat quality matters and that ultra-processed food consumption is a concern, but those two things are not the same as condemning seed oils specifically. If your diet is heavy in ultra-processed food containing seed oils, that is a problem. But the evidence suggests the ultra-processing, the excess energy, the refined carbohydrates and the low fibre are doing most of the heavy lifting in terms of harm, not the oil itself.

    Rapeseed oil specifically: a nuance the debate usually skips

    Most online content about seed oils focuses on American dietary patterns and American products: soybean oil is the dominant culprit in US-centric discussions. In the UK, the picture is different. Rapeseed oil has a much more favourable fatty acid profile than sunflower oil, with a lower omega-6 to omega-3 ratio and a reasonable monounsaturated fat content. Cold-pressed rapeseed oil, in particular, retains some polyphenols with mild antioxidant properties.

    This matters because a lot of the inflammatory claims circulating online are lifted from US sources and applied wholesale to the British context without adjustment. The seed oils in your average British supermarket trolley are not identical in composition to what American commentators are warning about. That does not make rapeseed oil a health food, but it makes the blanket condemnation less well-founded here than the content suggests.

    Where the anti-seed oil crowd has a point

    I do not want to dismiss every concern, because some of them are worth taking seriously. Heat stability is a real issue: seed oils high in PUFAs are more prone to oxidation at high cooking temperatures than olive oil or butter, producing degradation products including aldehydes. The degree to which this is clinically significant under normal home cooking conditions is debated, but the chemistry is real. If you are deep-frying regularly in sunflower oil and reusing it multiple times, switching to a more stable fat is not irrational.

    The omega-6 to omega-3 ratio argument also has some support. The concern is not that linoleic acid is inherently toxic but that a diet very high in omega-6 relative to omega-3 may shift the inflammatory balance in a direction that is not ideal. The practical answer to this is less about cutting seed oils and more about increasing omega-3 intake through oily fish or a supplement. This connects to what I covered in the blog’s earlier piece on whether supplement use is justified for common UK dietary shortfalls; the answer depends heavily on what the rest of your diet looks like.

    What should UK adults actually do?

    The practical answer is less dramatic than either camp wants it to be. Seed oils in moderate amounts, used for everyday cooking, are unlikely to be meaningfully harming you based on the current evidence. The inflammation crisis being attributed to sunflower oil in your stir-fry is probably more accurately attributed to a diet low in vegetables, fibre and oily fish, and high in ultra-processed food overall.

    That said, there is no strong reason to maximise seed oil consumption either. Using olive oil or cold-pressed rapeseed oil for everyday cooking is a reasonable preference, especially for flavour. Keeping omega-3 intake adequate, whether through two portions of oily fish per week (as recommended by the NHS) or a quality supplement, matters more than obsessing over which oil is in the pan.

    The culture war framing around seed oils is ultimately a distraction. The British diet has real problems, including chronically low fibre intake, insufficient protein for many older adults, and widespread omega-3 deficiency. Fixating on a single ingredient, framed as either poison or perfectly safe, usually means missing the bigger picture. Evidence-based dietary thinking is less satisfying than a clear villain, but it is more likely to actually help you. And if you have concerns about inflammation, chronic fatigue or systemic symptoms that do not resolve, that conversation belongs with your GP, not an algorithm. You might also find it useful to read about how the NHS currently handles complex fatigue conditions, where the gap between online certainty and clinical reality is similarly stark.

    Frequently Asked Questions

    Are seed oils causing inflammation in people eating a typical British diet?

    The current systematic review evidence does not support the claim that moderate seed oil consumption causes clinically significant inflammation in otherwise healthy adults. The stronger risk factors in the British diet are low fibre, low omega-3 intake and high ultra-processed food consumption. Seed oils are a component of that processed food problem, but the evidence does not single them out as the primary driver.

    Is rapeseed oil (vegetable oil) as bad as sunflower or soybean oil?

    No, and this distinction matters for UK readers. Cold-pressed rapeseed oil has a better omega-6 to omega-3 ratio than sunflower oil and a reasonable monounsaturated fat content, making it closer to olive oil in profile than to high-linoleic oils. Much of the anti-seed oil content online is based on American dietary patterns dominated by soybean oil, which does not translate directly to the UK context.

    Should I switch from vegetable oil to butter or olive oil for cooking?

    Using olive oil or cold-pressed rapeseed oil for everyday cooking is a reasonable choice, particularly for moderate-heat cooking. Butter is fine in moderate amounts for those without cardiovascular risk factors. What matters more than the specific oil choice is the overall dietary pattern: adequate fibre, vegetables, protein and omega-3 intake will have a far greater effect on health outcomes than swapping one cooking fat for another.

  • Chronic Fatigue Syndrome and the Long NHS Wait: What ME/CFS Patients in the UK Are Actually Facing in 2026

    Chronic Fatigue Syndrome and the Long NHS Wait: What ME/CFS Patients in the UK Are Actually Facing in 2026

    Myalgic encephalomyelitis, or ME/CFS, affects an estimated 250,000 people in the UK according to figures cited by the NICE guideline published in October 2021. For most of them, getting a diagnosis, let alone effective treatment, remains one of the most exhausting bureaucratic ordeals the NHS has to offer. I’ve spoken to patients who waited three years just to see a specialist. That isn’t a horror story outlier, it’s closer to routine. Understanding what ME/CFS NHS UK 2026 actually looks like on the ground matters, because the gap between what the updated guidelines promise and what patients experience is still wide.

    A tired woman waiting in an NHS hospital corridor, representing the long waits faced by ME/CFS NHS UK 2026 patients
    Photo by RDNE Stock project on Pexels

    What the 2021 NICE guidelines changed

    The 2021 overhaul was significant. NICE formally removed graded exercise therapy (GET) as a recommended treatment, along with cognitive behavioural therapy as a primary intervention aimed at reversing the condition. Both had been recommended for years, based largely on the PACE trial, a study that drew sustained methodological criticism from patient groups and independent researchers alike. The new guidelines acknowledged that ME/CFS is a serious, complex, chronic condition and that pushing patients through structured exercise programmes can worsen symptoms rather than improve them.

    This was a meaningful shift in tone, if not yet in practice. What the guidelines also introduced was clearer diagnostic criteria, a recommendation that diagnosis should be considered after three months of symptoms (rather than six, as previously stipulated), and a requirement for a positive energy management strategy called pacing. The guidelines explicitly state that any intervention should be designed around the patient’s energy limits, not around pushing past them.

    Why waiting times for ME/CFS are still damaging

    The guidelines are one thing. Commissioning and capacity are another. Specialist ME/CFS services across England are patchy at best. Some regions have dedicated clinics with reasonable referral pathways; others rely on general fatigue services that were designed for a broader population and may not have the expertise to manage post-exertional malaise properly. In parts of Wales and Scotland, specialist provision is even thinner.

    NHS England data and patient advocacy organisations including ME Association and Action for ME have consistently flagged that referral-to-appointment waits of 12 to 24 months are not uncommon. For a condition where early, accurate management can reduce the risk of severe deterioration, that wait is clinically meaningful, not just inconvenient. A proportion of patients deteriorate significantly whilst waiting, sometimes to the point of becoming housebound or bedbound.

    There’s also a diagnostic delay that precedes the specialist referral. Many GPs are still not confident diagnosing ME/CFS, partly because the condition has no definitive biomarker test. Patients frequently cycle through cardiology, neurology, and rheumatology before anyone takes a structured ME/CFS history. The NICE guidelines try to address this by giving GPs clearer criteria, but changing clinical habits takes time and training investment that hasn’t fully materialised.

    What removing GET actually means for patients day to day

    Removing GET from the guidelines doesn’t mean patients are being offered nothing. The emphasis has shifted to pacing, which involves working within an individual’s energy envelope, a concept that sounds simple but requires genuine clinical support to implement well. The problem is that pacing support is not standardised. Some patients get detailed, personalised plans from occupational therapists with ME/CFS experience. Others get a leaflet.

    Low-dose naltrexone, rintatolimod, and various other pharmacological approaches remain either unlicensed or evidence-light in the UK context, so the NHS isn’t widely offering them. Pain management, sleep support, and symptom relief for associated conditions like orthostatic intolerance are available, but access varies by postcode. If you happen to live near one of the NHS specialist clinics with a multidisciplinary team, your experience will be substantially different from someone in a rural area without one.

    It’s also worth noting that the long COVID cohort, which shares significant symptomatic overlap with ME/CFS, has created both an additional demand on fatigue services and, arguably, increased research momentum. Some clinicians believe long COVID has done more to normalise the physiological reality of ME/CFS than two decades of patient advocacy. That’s a bitter irony, but if it accelerates research funding and clinical training, the downstream effect for the existing ME/CFS population may be positive.

    What emerging research suggests about underlying mechanisms

    The past few years have seen genuinely promising mechanistic research. Studies from groups including Stanford Medicine and University College London have identified abnormalities in mitochondrial function, immune dysregulation, and autonomic nervous system signalling in ME/CFS patients. A 2023 study in Nature Communications found measurable energy metabolism impairments in ME/CFS patients compared with healthy controls, giving biological weight to what patients have described for decades, that their fatigue is not psychological unwillingness, but a physiological ceiling.

    Research into small fibre neuropathy as a possible contributor to ME/CFS symptoms has also gained traction, as has work on mast cell activation and viral persistence as potential triggers. None of this has yet translated into approved treatments, but it represents a substantive departure from the biopsychosocial model that dominated clinical thinking for so long. For patients who spent years being told their illness was primarily a product of unhelpful thinking patterns, that shift carries real weight.

    If you’re also managing conditions that complicate fatigue-related symptoms, the evidence around sedentary behaviour and cardiovascular health is worth reading carefully, given that many ME/CFS patients are forced into low activity by their condition. Similarly, understanding what inadequate fibre intake does beyond digestion is relevant for a population that often has restricted diets and gut symptoms. And given how frequently ME/CFS patients are told their symptoms may be psychiatric, the broader context around how the NHS handles contested or surging diagnostic categories offers useful perspective.

    Where things stand right now and what needs to change

    The NICE guidelines represent a genuine step forward. The science is moving in the right direction. But in 2026, the practical reality for most ME/CFS patients in the UK is still one of long waits, inconsistent care, and a system that hasn’t yet matched its updated guidance with the infrastructure to deliver it. More specialist clinics, better GP training, and investment in the research pipeline are all necessary, and none of them happen quickly.

    What I’d say to anyone navigating this right now: the guidelines are on your side. Print them out, share them with your GP, and ask specifically whether any management plan you’re being offered aligns with the 2021 NICE criteria. Patient organisations like the ME Association offer clear, accurate summaries of what you’re entitled to ask for. You are not imagining it. The biology is real, the research is catching up, and the clinical establishment, slowly, is too.

    Frequently Asked Questions

    How long does it take to get an ME/CFS diagnosis on the NHS in 2026?

    Diagnosis timelines vary widely depending on where you live. Many patients wait 12 to 24 months for a specialist appointment after GP referral, and diagnostic delays before that referral are common because there’s no definitive biomarker test. The 2021 NICE guidelines recommend that ME/CFS should be considered after three months of symptoms, which is intended to speed up the process at GP level.

    Why was graded exercise therapy removed from ME/CFS treatment guidelines?

    NICE removed graded exercise therapy (GET) in its 2021 guideline update because evidence indicated it could worsen symptoms rather than help, particularly through triggering post-exertional malaise. The primary basis for GET had been the PACE trial, which faced significant methodological criticism. The updated guidelines replaced GET with an energy management approach called pacing.

    What treatment is available for ME/CFS on the NHS now?

    The current NHS approach centres on pacing, which means helping patients manage their activity within their personal energy limits. Symptom management for pain, sleep difficulties, and conditions like orthostatic intolerance is also offered. Access to specialist multidisciplinary teams varies considerably by region, and there are no pharmacological treatments currently licensed specifically for ME/CFS in the UK.

    Is ME/CFS related to long COVID?

    There is significant symptomatic overlap between ME/CFS and long COVID, including post-exertional malaise, cognitive difficulties, and fatigue that doesn’t improve with rest. Some researchers believe long COVID is triggering ME/CFS in a proportion of patients, and the surge in long COVID cases has brought additional research attention and funding to the underlying mechanisms. NICE guidance on ME/CFS is considered relevant for long COVID fatigue management.

    What does new research say about the cause of ME/CFS?

    Recent research has identified abnormalities in mitochondrial energy metabolism, immune system function, autonomic nervous system signalling, and small fibre neuropathy in ME/CFS patients. A study published in Nature Communications in 2023 found measurable energy metabolism impairments, offering biological evidence for the physiological basis of the condition. While no approved treatments have yet emerged from this work, it has substantively shifted scientific understanding away from purely psychological explanations.

  • Magnesium Deficiency in the UK: Who Is Actually at Risk and Whether the Supplement Boom Is Justified

    Magnesium Deficiency in the UK: Who Is Actually at Risk and Whether the Supplement Boom Is Justified

    The supplement aisle has changed. Where once you’d find a modest row of multivitamins, there are now entire sections dedicated to magnesium alone, offered in a bewildering range of forms: glycinate, threonate, malate, citrate, oxide. Social media has done a lot of the marketing work here, with creators attributing poor sleep, anxiety, muscle cramps, and fatigue to a single missing mineral. The question worth asking, though, is whether magnesium deficiency UK health data actually supports this level of concern, or whether most of us are buying supplements we don’t need.

    Supplement capsules on a wooden table illustrating the growing discussion around magnesium deficiency UK
    Photo by ready made on Pexels

    What the National Diet and Nutrition Survey actually shows

    The National Diet and Nutrition Survey (NDNS), run jointly by the FSA and the Department of Health and Social Care, provides the most reliable picture of what British adults are actually eating. The most recent rolling programme data consistently shows that a meaningful proportion of UK adults fall below the Reference Nutrient Intake (RNI) for magnesium. For adult men, the RNI sits at 300mg per day; for adult women, 270mg per day.

    The NDNS figures show that teenage girls and women aged 19 to 64 are the groups most likely to have intakes below the lower reference nutrient intake, which is the threshold at which deficiency becomes a genuine physiological concern. Men over 65 also appear in the data as a higher-risk group. But here’s the nuance that most supplement marketing glosses over: falling below the RNI is not the same as being clinically deficient. The RNI is set deliberately high, covering the needs of around 97% of the population. Many people eating slightly below it are fine.

    What clinical magnesium deficiency actually looks like

    True clinical deficiency, called hypomagnesaemia, is detectable via a serum blood test and produces symptoms including muscle cramps, tremor, cardiac arrhythmias, and in severe cases, seizures. It is relatively rare in otherwise healthy adults. The people genuinely at risk are those with type 2 diabetes (where urinary magnesium loss is higher), those with inflammatory bowel conditions like Crohn’s disease (where absorption is compromised), people taking certain medications including proton pump inhibitors and diuretics, and heavy alcohol users. I’d also add people who have had significant sections of their small intestine removed for any reason.

    If you have one of those conditions, the conversation about magnesium is legitimate and worth having with a GP. For the rest of the population, the honest answer is that most people eating a varied diet are not clinically deficient, even if their intake doesn’t look ideal on paper. If you’re interested in how dietary absorption and gut health interact with nutrient levels more broadly, it’s worth reading about how fibre intake affects far more than just digestion, since gut integrity plays a role in how efficiently any mineral is absorbed.

    Natural food sources of magnesium including pumpkin seeds and dark chocolate relevant to magnesium deficiency UK dietary intake
    Photo by Vie Studio on Pexels

    Are glycinate and threonate actually better?

    The premium supplement market leans heavily on two forms: magnesium glycinate and magnesium L-threonate. Glycinate is marketed as being gentler on the stomach and better absorbed than oxide. Threonate is sold with claims around cognitive function and brain health. Both are considerably more expensive than magnesium citrate or oxide.

    On the bioavailability question, the evidence does suggest that oxide is poorly absorbed relative to other forms, so if you’re going to supplement, glycinate and citrate are reasonable choices. The threonate claims are more specific. The research most cited comes from animal studies and a small number of human trials, some of which were funded by the manufacturer. The 2016 trial published in the Journal of Alzheimer’s Disease by Slutsky et al. showed promising results in older adults with cognitive complaints, but the sample sizes were small. I’d characterise the brain health evidence as genuinely interesting but nowhere near established enough to justify the price premium most UK retailers charge.

    Retailers including HealthPod Mansfield stock a range of magnesium forms, which is useful if you’re trying to compare options and understand what you’re actually buying rather than just defaulting to whatever’s trending on a given week.

    The sleep and anxiety claims

    This is where the online conversation runs furthest ahead of the science. Magnesium does have a role in regulating GABA receptors, which are involved in calming neural activity, and it interacts with melatonin pathways. That’s a real mechanism. The clinical evidence for supplementation improving sleep in people who are already replete, however, is thin. A 2021 systematic review in BMC Complementary Medicine and Therapies found modest improvements in subjective sleep quality in older adults, but the effect sizes were small and the studies had notable methodological weaknesses.

    For anxiety, the picture is similarly cautious. There’s observational data suggesting lower dietary magnesium correlates with higher anxiety scores, but correlation between dietary intake and mental health is notoriously difficult to interpret causally. If sleep and anxiety are a concern, addressing the structural causes, including screen exposure, irregular schedules, and chronic stress, is likely to do more than any supplement. If you’re curious about how one common habit may be affecting your sleep more than you realise, this piece on how smartphones disrupt sleep is a useful companion read.

    Who should actually consider supplementing

    My read of the evidence is this: if you have a condition that raises your risk of genuine deficiency (type 2 diabetes, IBD, long-term PPI use), it’s worth discussing a blood test with your GP before buying anything. If your test comes back showing hypomagnesaemia, supplementing under guidance makes sense. If you’re a generally healthy adult eating a diet that includes green vegetables, nuts, wholegrains, and legumes, you’re probably meeting your needs from food.

    The food sources of magnesium are worth knowing. Per 100g, pumpkin seeds offer around 550mg, dark chocolate around 230mg, cooked spinach around 80mg, and wholemeal bread around 60mg. These aren’t exotic or expensive foods. A diet that’s consistently low in these things is more likely to be a broader dietary quality problem than a single-mineral problem, and no supplement corrects a poor diet pattern.

    There’s a broader issue worth naming. The wellness supplement market, now worth over £500 million annually in the UK according to industry figures, runs on the anxiety that we’re missing something essential. Sometimes that anxiety is justified, as we’ve seen with vitamin D in the UK where deficiency is genuinely widespread and the evidence for supplementation is solid. With magnesium, the picture is more complicated. Certain populations need to take it seriously. Most don’t need to spend £30 a month on threonate capsules. Getting that distinction right matters, and I’d argue the first step is looking at the NDNS data rather than a YouTube thumbnail. If dietary patterns and their downstream health consequences interest you, the evidence on how ultra-processed food affects brain function is another thread worth pulling.

    Frequently Asked Questions

    How common is magnesium deficiency in the UK?

    Subclinical low intake is fairly common, particularly among teenage girls and older adults, based on NDNS data. However, true clinical deficiency (hypomagnesaemia) is relatively rare in otherwise healthy British adults and is most likely in people with specific conditions such as type 2 diabetes, Crohn’s disease, or long-term use of certain medications.

    What is the difference between magnesium glycinate and magnesium oxide?

    Magnesium oxide has poor bioavailability, meaning much of it passes through without being absorbed. Glycinate and citrate forms are better absorbed and less likely to cause digestive discomfort. For most people who do need to supplement, glycinate or citrate are the more practical choices, though they tend to cost more.

    Can magnesium supplements improve sleep?

    Magnesium has a role in regulating GABA receptors, which support calm neural activity. However, the clinical evidence that supplementing improves sleep in people who are not actually deficient is weak. A 2021 systematic review found modest benefits mainly in older adults, with small effect sizes and significant study limitations.

    Is magnesium L-threonate worth the extra cost for brain health?

    The brain health evidence for threonate is based largely on animal studies and a small number of industry-funded human trials. Results are promising but not yet robust enough to justify its significant price premium over standard forms. I’d treat the cognitive claims as interesting rather than established.

  • Time-Restricted Eating in Practice: What the Latest Trials Actually Show for UK Adults Trying to Lose Weight

    Time-Restricted Eating in Practice: What the Latest Trials Actually Show for UK Adults Trying to Lose Weight

    Time-restricted eating has become one of the most searched diet approaches in Britain. The 16:8 version, where you eat within an eight-hour window and fast for sixteen, sits across social media feeds promising fat loss, metabolic reset, and energy clarity. But what does the actual clinical evidence say? I’ve spent time going through the recent randomised controlled trials and meta-analyses so you don’t have to wade through the hype yourself.

    The short version: there are genuine, modest effects worth knowing about. There are also some significant caveats that the wellness content machine consistently skips past.

    Person eating a balanced meal, illustrating time restricted eating UK evidence in practice
    Photo by Mikael Blomkvist on Pexels

    What randomised controlled trials actually show

    The most rigorous recent work on time-restricted eating comes from a 2023 meta-analysis published in The Lancet Regional Health, which pooled data from 27 RCTs covering more than 1,500 participants. The headline finding: people assigned to time-restricted eating lost an average of around 1.5 kg more than control groups over periods of eight to twenty-four weeks. That is real. It is also modest, and the authors were careful to note that adherence varied considerably between trials, and that many studies ran for too short a period to assess long-term outcomes.

    A 2024 trial from researchers in California (published in NEJM Evidence) attracted a lot of UK press coverage because it directly compared 16:8 fasting against straightforward calorie restriction over a full year. Both groups lost similar amounts of weight. The time-restricted eating group did not lose significantly more, despite the promise of metabolic advantages. What the trial did show is that time-restricted eating can be a useful tool for reducing overall calorie intake without requiring people to count anything, which for many people is its real practical value.

    A 2025 meta-analysis in Obesity Reviews looked specifically at metabolic markers. It found small but consistent improvements in fasting insulin and blood pressure in the time-restricted eating groups, though effect sizes were generally larger in people who were already clinically obese rather than those who were simply overweight. The mechanisms proposed include circadian alignment (eating patterns that match daylight hours appear to improve insulin sensitivity) and reduced late-evening calorie consumption, which is common in British eating habits.

    Where NICE guidance sits on this

    NICE obesity guidance (NG238, updated in 2023) recommends a whole-systems approach to weight management, emphasising total energy balance, behavioural support, and addressing wider determinants like food environment and mental health. It does not specifically endorse or recommend time-restricted eating as a weight loss method, which tells you something. The guidance is publicly available on nice.org.uk and is worth reading if you want to understand where evidence-based medicine actually draws its lines on diet approaches.

    That does not mean time-restricted eating is discouraged. It means it has not met the evidence threshold for a formal recommendation in a clinical setting. For most otherwise healthy adults who want a practical framework for eating less without tracking macros, the current evidence does not rule it out. It just does not write it a prescription either.

    The specific problem with British eating patterns

    UK dietary data from the National Diet and Nutrition Survey consistently shows that British adults consume a significant proportion of their daily calories after 6pm. Crisps, biscuits, takeaways, alcohol on weeknights: the classic late-evening eating pattern is very common here. If someone adopts a 12pm to 8pm eating window, they are likely cutting the most calorie-dense part of their day anyway. That is where a decent chunk of the weight loss effect probably comes from, not from anything metabolically special about fasting itself.

    I’d argue this is actually useful information, because it means you can achieve a similar result by simply stopping eating earlier in the evening, even without a formal fasting protocol. The structure of time-restricted eating just makes that behavioural change easier for some people to stick to.

    There is also the question of protein. Several UK dietitians have raised a legitimate concern: people who compress their eating window sometimes struggle to hit adequate protein targets across fewer meals. If you’re over 50, this matters more than most online content acknowledges. Research consistently shows that muscle maintenance in older adults depends heavily on both total protein intake and its distribution across meals. If you’re using time-restricted eating, I’d strongly recommend reading about strength training and protein needs for adults over 50 before you compress your eating window too aggressively.

    Who should be cautious

    Time-restricted eating is not appropriate for everyone. People with a history of disordered eating should approach any structured fasting protocol carefully and, ideally, with support from a GP or registered dietitian. The same applies to people with type 1 diabetes, anyone on insulin or sulphonylureas, and those who are pregnant or breastfeeding.

    There is also emerging (though not yet conclusive) research suggesting that prolonged calorie restriction within very narrow windows may affect cortisol rhythms, which can interact with existing anxiety or sleep difficulties. If you already struggle with sleep quality, it is worth noting that the relationship between eating timing and sleep is more complex than most 16:8 content acknowledges. Disrupted eating schedules can compound the kind of issues discussed in the context of broader nutritional gaps in British diets that are already widespread.

    The outsized claims to ignore

    Autophagy. This is the big one. The claim that 16:8 fasting triggers significant cellular autophagy (cellular self-cleaning) in humans is heavily overstated. Most autophagy research in humans comes from studies of much longer fasting periods, often 48 hours or more. The evidence that a 16-hour fast meaningfully increases autophagy in otherwise well-fed people is weak. Do not let that claim be the reason you pick up this eating pattern.

    Metabolic rate increases from fasting are also frequently cited and consistently misrepresented. Short-term fasting does show a small increase in resting metabolic rate in some studies. But this effect is transient and does not persist in the way that chronic calorie restriction can sometimes reduce metabolic rate. The long-term metabolic picture from time-restricted eating looks much more neutral than either the boosters or the sceptics claim.

    One thing I find genuinely useful from the trial data: time-restricted eating appears to reduce overall calorie intake by roughly 200 to 500 kcal per day for most adherent participants, without requiring them to count a single thing. For the many UK adults who find calorie tracking unsustainable, that is a meaningful practical advantage. Combined with adequate protein, regular meals within the window, and some resistance exercise, it can be a reasonable component of a sensible approach to weight management. Just not a miracle.

    If you are managing something like Crohn’s disease or another condition where food timing and gut response interact in complex ways, it is especially important not to apply generic fasting advice without proper guidance. The landscape of diet and chronic illness is covered in more detail in our piece on why IBD patients are being let down by social media diet advice.

    The evidence for time-restricted eating in the UK context is genuinely there. It is just smaller and more conditional than the people selling courses and meal plans would like you to believe.

  • The ADHD Diagnosis Surge in British Adults: What Is Driving It and What the NHS Can and Cannot Offer

    The ADHD Diagnosis Surge in British Adults: What Is Driving It and What the NHS Can and Cannot Offer

    Something significant is happening in British mental health. Adult ADHD diagnosis UK NHS referrals have risen sharply over the past five years, and the system was not built to absorb it. NHS England data shows that the number of adults on waiting lists for ADHD assessment has grown substantially, with some trusts reporting waits of three to five years. Meanwhile, a private diagnosis industry has expanded rapidly to fill the gap. Whether that is a good thing depends heavily on who you ask and how well the diagnosis is followed up.

    Adult woman in a GP consultation discussing adult ADHD diagnosis UK NHS pathway
    Photo by cottonbro studio on Pexels

    I want to be clear about what this article is not doing: it is not arguing that ADHD is overdiagnosed, nor that every adult seeking assessment is simply chasing a label. The evidence for ADHD as a genuine neurodevelopmental condition affecting adults is well established. NICE guideline NG87, updated in 2019, confirms that ADHD persists into adulthood in around 60% of children diagnosed, and that many adults were simply missed in childhood, particularly women, whose presentations often differ from the hyperactive stereotype.

    Why referral numbers have risen so quickly

    Several factors have collided at once. Social media has made ADHD more visible. TikTok and Instagram have produced millions of posts describing the experience of inattentive ADHD in adults, particularly among women, and for many people who had spent years feeling disorganised, overwhelmed or unable to sustain focus, those descriptions felt like a revelation. That is not inherently problematic. Awareness raises access. The concern is when self-identification bypasses formal assessment entirely, or when commercial platforms exploit the demand.

    Pandemic disruptions likely played a role too. Adults who previously managed their symptoms within a structured environment found remote working either removed their coping mechanisms or, conversely, gave them the space to notice how much effort everyday tasks actually required. A spike in referrals from around 2021 onwards is consistent with that pattern.

    Beyond the social drivers, there is a simpler explanation: the cohort of adults who were missed as children is large. The NHS did not routinely assess girls for ADHD in the 1980s and 1990s. Many adults in their thirties and forties presenting now are not experiencing a new condition; they are finally being seen.

    What the NHS assessment pathway actually looks like

    In theory, the pathway is straightforward. A GP refers a patient to a community mental health team or a specialist ADHD service, where a psychiatrist or appropriately trained clinician carries out a structured assessment using tools such as the Conners Adult ADHD Rating Scales or the Diagnostic Interview for ADHD in Adults (DIVA). NICE guidelines recommend that diagnosis is not made on the basis of a single questionnaire and that assessment considers the person’s history across multiple life settings.

    In practice, the process is far slower. NHS England published data in 2023 showing that some regions had waiting lists exceeding 2,000 patients for adult ADHD services. Staffing shortfalls in psychiatry, combined with demand that has roughly doubled in some trusts, mean that the theoretical pathway and the lived reality are quite different things.

    GPs are also in a difficult position. Many report feeling under-equipped to screen effectively, and without a clear referral pathway or adequate capacity at the receiving end, they face a no-win situation. Some decline to refer, some refer and patients wait years, and some sign off prescriptions from private providers they have limited ability to verify. The structural tension between what workplace wellbeing systems promise and what they deliver has a direct parallel here: the gap between policy intent and operational reality is where people fall through.

    The private diagnosis market: useful or problematic?

    Private ADHD assessment services have grown substantially. Platforms such as Psychiatry-UK, ADHD 360, and various individual psychiatry practices offer assessments that can take place within weeks rather than years. Costs vary, but a full private assessment typically runs from £400 to £900, putting it beyond reach for many on lower incomes. That is a real equity concern.

    The quality of private assessments also varies. The Care Quality Commission (CQC) has raised concerns about some providers, and in 2023 NHS England temporarily suspended the right-to-choose pathway with Psychiatry-UK following a review. That suspension was later lifted with additional oversight requirements, but it illustrated that speed and rigour do not always coexist. A short questionnaire and a 45-minute video call is not the same as a thorough clinical assessment, regardless of who delivers it.

    Diagnosis without follow-up is another problem. Private providers can diagnose and prescribe, but titrating stimulant medication correctly requires ongoing monitoring. If a patient cannot afford continued private appointments and their GP is unwilling or unable to take on shared care, they may end up with a diagnosis on paper and no functional support. This connects to a broader pattern of people being formally acknowledged by a system that then leaves them unsupported.

    What actually helps once you have a diagnosis

    Medication is effective for many adults with ADHD. Methylphenidate (branded as Ritalin or Concerta) and lisdexamfetamine (Vyvanse) are the two most commonly prescribed in the UK, and the clinical evidence for their efficacy is robust. NICE recommends medication as first-line treatment for adults with moderate to severe impairment, with psychological intervention recommended alongside or for those who prefer it.

    Cognitive behavioural therapy adapted for ADHD can help with organisation, time management and emotional regulation. The NHS offers this in some areas through IAPT-successor services, though availability is patchy. Many adults end up accessing it privately or relying on self-help approaches.

    Sleep, exercise and routine structure also matter more than most people expect. The relationship between physical activity and mental health outcomes is well documented, and for adults with ADHD specifically, aerobic exercise has shown measurable effects on dopamine regulation in several studies. This is not an alternative to treatment; it is part of the picture.

    What needs to change

    The NHS workforce plan published in 2023 acknowledged psychiatry staffing shortfalls, but solutions at the required scale have not materialised quickly. Some integrated care boards have begun commissioning community ADHD teams separate from general adult mental health services, which helps with capacity. Others have introduced tiered screening tools that allow GPs to triage more effectively before formal referral.

    What would genuinely help is a nationally consistent shared-care framework so that private diagnoses can be properly absorbed into NHS prescribing and monitoring without leaving GPs in an impossible position. The current situation, where GPs are individually deciding whether to accept prescribing responsibilities for privately diagnosed patients with no standardised guidance, is neither safe nor fair to anyone involved.

    For people currently waiting, the honest picture is: the waits are real, the private route has genuine risks alongside its speed, and medication, where appropriate, works. Getting a diagnosis matters. So does having adequate support once you have one.

    Frequently Asked Questions

    How long is the NHS wait for adult ADHD assessment in the UK?

    Waiting times vary significantly by region, but many NHS trusts are currently reporting waits of two to five years for adult ADHD assessment. Some areas have improved through right-to-choose referral options, though availability and quality differ between providers.

    Can a GP diagnose ADHD in an adult in the UK?

    GPs in the UK cannot formally diagnose ADHD, that requires a specialist assessment by a psychiatrist or appropriately trained clinician. A GP can refer you to the relevant NHS service or acknowledge a private diagnosis for shared-care prescribing, though practices vary.

    Is private ADHD diagnosis in the UK reliable?

    Quality varies between providers. Reputable services use structured diagnostic interviews such as DIVA alongside clinical history review, which takes time. The CQC has raised concerns about some providers, so it is worth checking registration and whether the provider offers proper post-diagnosis support and medication monitoring.

    What medication is prescribed for adult ADHD on the NHS?

    NICE guidelines recommend methylphenidate as first-line medication for most adults, with lisdexamfetamine as an alternative. Both are available on NHS prescription. Medication needs to be titrated carefully, which requires ongoing GP or specialist appointments.

  • Workplace Wellbeing Programmes in the UK: Why the Evidence for Most of Them Is Surprisingly Weak

    British employers spent an estimated £83 billion on lost productivity due to poor employee health in 2023, according to the government’s own Health is Everyone’s Business review. The response, across countless HR departments, has been to roll out wellbeing programmes: lunchtime yoga, mental health days, employee assistance programme (EAP) hotlines, mindfulness apps, and the occasional fruit bowl. I’d argue the instinct is good. The execution, in most cases, is not backed by anything close to solid evidence.

    The uncomfortable truth is that when you dig into the research, particularly the Cochrane systematic reviews and NICE’s own workplace health guidance, the returns on most of these interventions are either marginal, inconsistent, or impossible to measure reliably. That does not mean organisations should abandon the effort. It means they should direct it somewhere it actually works.

    What Cochrane reviews actually say about common workplace wellbeing interventions

    Cochrane is as rigorous as health research gets. Its reviews synthesise findings across multiple randomised controlled trials and are treated as the gold standard by NICE, the NHS, and most public health bodies. On workplace wellbeing, the picture is sobering.

    A 2020 Cochrane review on workplace physical activity interventions found that while some programmes modestly reduced absenteeism, the quality of evidence was generally low to very low. Effect sizes were small and often failed to persist beyond the intervention period. Yoga and relaxation programmes showed some short-term benefit on mental wellbeing scores, but the authors were clear: there is insufficient evidence to conclude these translate into sustained health improvements or meaningful reductions in presenteeism.

    EAP hotlines are perhaps the most widely adopted feature of UK workplace wellbeing programmes, offered by the majority of organisations with more than 250 employees. Yet a 2021 analysis published in the Journal of Occupational Health Psychology found uptake rates often sit below 5% of the workforce, and the evidence that EAPs reduce clinical-level anxiety or depression in employees who do use them remains limited. Self-reported satisfaction is reasonably high, but self-reported satisfaction is not the same as improved health.

    Why NICE guidance points in a different direction

    NICE’s guidance on mental health at work (NG212) and its broader workplace health framework do not recommend yoga sessions or mental health days as primary interventions. They recommend structural changes: job redesign to reduce excessive demands, giving employees genuine autonomy over how they work, addressing management behaviour, and ensuring access to occupational health services for those who need them.

    The distinction matters. A mental health day might give an individual a brief respite from a stressful environment, but it does nothing about the stressful environment itself. NICE’s position, broadly, is that interventions targeting the individual whilst leaving the work context unchanged are unlikely to produce lasting improvement. I think that is exactly right, and it is frustrating how rarely employer communications acknowledge it.

    There is also a socioeconomic dimension that most wellbeing programme reviews miss entirely. UK employer surveys conducted by the CIPD (Chartered Institute of Personnel and Development) consistently show that the employees who participate in wellbeing activities tend to be those already in better health. Employees dealing with serious stress, financial insecurity, or chronic illness are the least likely to join a yoga class or call a helpline. The people who most need support are systematically the least likely to access what is on offer.

    The specific problem with mental health days

    Mental health days have received enormous media coverage over the past few years, and several large UK employers have introduced them as a formal entitlement. The intention is reasonable: to reduce stigma and give employees space to recover. The evidence that they achieve this is thin.

    A single day off does not treat clinical depression. It does not reduce chronic work-related stress. It does not address the presenteeism problem, where employees come to work whilst mentally unwell and operate at a fraction of their capacity. According to the CIPD’s 2024 Health and Wellbeing at Work report, presenteeism is still far more common in UK workplaces than absenteeism, yet it receives comparatively little attention in wellbeing strategies.

    This connects to a broader pattern: organisations tend to adopt interventions that are visible, easy to communicate in a press release, and unlikely to require meaningful structural change. Yoga classes are easier to organise than a proper job-demand audit. A mental health day makes for good social media content. Reviewing line manager behaviour does not.

    What actually shows a reasonable evidence base

    I do not want to leave this as a pure critique without acknowledging what does appear to work. Several interventions have a more credible evidence base, even if the effect sizes remain modest.

    Cognitive behavioural therapy-based programmes delivered by qualified practitioners, either face-to-face or through accredited digital platforms, consistently outperform generic mental health apps in reducing anxiety and depression symptoms. The key word is qualified: the evidence does not transfer to self-guided mindfulness apps, which have proliferated in UK workplace wellbeing packages despite very limited trial evidence for population-level benefit.

    Occupational health referrals, when they happen early rather than as a last resort, are associated with better return-to-work outcomes for employees with musculoskeletal problems and common mental health conditions. The problem is that most UK employers still do not have direct access to occupational health services, a gap the government’s Occupational Health Task Force acknowledged in its 2023 report.

    Physical activity, when integrated into the working day through flexible scheduling or active travel incentives, does show some meaningful benefit for cardiovascular health and mood, especially in sedentary desk workers. I’ve written elsewhere about the specific cardiovascular risks of sedentary work and how little exercise it actually takes to begin reversing them. The point is not that movement is pointless; it is that a lunchtime yoga session offered as an optional extra, with no structural support for attendance, does not qualify as a meaningful physical activity intervention.

    What employers should actually be asking

    If you are involved in designing or commissioning workplace health programmes, a few questions are worth putting plainly. What is the uptake rate, and who is using this? Is the intervention targeting individuals or the work environment? Is there a qualified clinical professional involved, or is this essentially a branded app and a poster campaign? And perhaps most importantly: what does the data actually show, not what do employees say they like about it?

    Likeability and efficacy are not the same thing. A fruit basket scores well on both employee satisfaction surveys and Instagram. It does not prevent burnout.

    The wellbeing industry in the UK is substantial and growing, and much of it is selling products and programmes on the basis of intent rather than outcome. Organisations genuinely committed to employee health need to apply the same rigour they would to any other business decision. That means reading the NICE guidance, looking at the Cochrane evidence, and being honest about whether what is currently on offer is improving anything that actually matters.

    There is real hope here too. Organisations that shift their focus toward management training, workload control, and proper clinical referral pathways do see improvements. The evidence for those approaches is stronger. They are just harder to put in a wellbeing brochure, and that is probably why most employers still have not done it.

    Frequently Asked Questions

    Do workplace wellbeing programmes actually work in the UK?

    The evidence is mixed, and often weak. Cochrane reviews and NICE guidance suggest that popular interventions like yoga sessions, mental health days, and EAP hotlines show limited or inconsistent effects on measurable health outcomes. Structural changes to workload and management practice tend to show stronger results.

    What does NICE recommend for employee mental health at work?

    NICE guidance (NG212) prioritises reducing excessive job demands, improving employee autonomy, and addressing management behaviour over individual-focused perks. It emphasises organisational and environmental changes rather than optional wellness activities.

    Are employee assistance programme (EAP) hotlines effective?

    EAPs are widely available in UK workplaces but uptake is typically below 5% of the workforce. Evidence for their ability to reduce clinical anxiety or depression at a population level is limited, though individual users often report satisfaction with the service.

    Which workplace health interventions have the best evidence behind them?

    CBT-based programmes delivered by qualified practitioners, early occupational health referrals, and genuine integration of physical activity into the working day have stronger evidence bases than most standard wellbeing packages. The quality of delivery matters significantly.

    Why do employers keep offering wellbeing programmes if the evidence is weak?

    CIPD surveys suggest many employers choose interventions that are easy to implement and communicate, rather than those with the strongest clinical evidence. Visible, low-friction activities like yoga classes or app subscriptions are simpler to deploy than meaningful structural workplace changes.

  • Caffeine Dependence Is More Clinically Significant Than Most UK Adults Realise

    Most people who drink three or four cups of coffee a day would laugh if you called them dependent. I’d have said the same thing a few years ago. But caffeine dependence is now a formally recognised clinical condition under the World Health Organisation’s ICD-11 classification system, and the UK’s consumption patterns put a meaningful proportion of the population squarely in the affected category. This isn’t scaremongering about your morning flat white. It’s worth understanding what the research actually says.

    How caffeine dependence is classified under ICD-11

    The ICD-11 (International Classification of Diseases, 11th Revision) includes caffeine dependence as a recognised disorder under the category of “substance dependence”. This was a significant shift from previous editions, where caffeine had a more ambiguous status. To meet the clinical threshold, a person needs to show three or more of the following over a 12-month period: a strong desire to consume caffeine, difficulty controlling intake, continued use despite knowing it causes harm, prioritising caffeine over other activities or obligations, tolerance (needing more to get the same effect), and withdrawal symptoms when use is reduced.

    That last criterion is where most people start to recognise themselves. Withdrawal symptoms are well-documented in the pharmacology literature: headaches, fatigue, difficulty concentrating, depressed mood, and irritability, typically beginning 12 to 24 hours after the last dose and peaking at 20 to 51 hours. A 2004 systematic review published in Psychopharmacology by Griffiths and Woodson, which later informed the ICD-11 criteria, found that withdrawal occurred reliably across study populations even at modest daily intakes of around 100mg, roughly one strong cup of coffee.

    UK caffeine consumption: where we actually stand

    The UK Food Standards Agency and the British Dietetic Association both note that most healthy adults can consume up to 400mg of caffeine per day without significant adverse effects. The European Food Safety Authority (EFSA) puts its guidance at a similar level. But “without adverse effects” is not the same as “without dependence”, and UK consumption data suggests many adults exceed 400mg without realising it.

    A standard 250ml mug of filter coffee contains roughly 140mg of caffeine. A double espresso from a chain like Costa or Caffè Nero can carry 200mg or more. Energy drinks, which have surged in popularity particularly among 16 to 34 year olds according to ONS dietary survey data, often contain 80mg per 250ml can, with larger formats containing considerably more. Add in tea (around 40-50mg per cup), pre-workout supplements, caffeinated soft drinks, and the occasional dark chocolate, and 500mg-plus daily totals are genuinely common without anyone consciously “overdoing it”.

    According to the Food Standards Agency, pregnant women are advised to limit caffeine to 200mg per day due to risks associated with foetal development, but monitoring of real-world intake remains patchy, and many people simply do not know how much they are consuming.

    What the pharmacology actually tells us

    Caffeine works primarily by blocking adenosine receptors in the brain. Adenosine is a neurotransmitter that accumulates throughout the day and promotes sleepiness; when caffeine occupies those receptors, you feel alert. The problem is that the brain adapts. With regular caffeine use, it upregulates adenosine receptors, meaning more receptors are created, and your baseline level of alertness without caffeine drops. You’re no longer drinking coffee to feel good; you’re drinking it to feel normal.

    This receptor adaptation is what makes caffeine dependence more than a habit in the casual sense. It’s a genuine neurological adjustment. Research from Johns Hopkins University, widely cited in pharmacology literature, demonstrated that around 50% of regular caffeine users experience clinically significant withdrawal symptoms when they stop, and roughly 13% experience symptoms severe enough to interfere with daily functioning. Those are not trivial numbers across a population of tens of millions of regular coffee and tea drinkers.

    There’s also a tolerance dimension that catches people off guard. If you’ve gradually increased your intake over years, you may be consuming significantly more caffeine than you were a decade ago, not because you wanted more, but because the previous amount stopped working. That escalating pattern is a key feature of pharmacological dependence, whether we’re talking about caffeine or anything stronger.

    Who is most affected by caffeine dependence in the UK

    Dependence doesn’t discriminate by demographic, but certain groups are more exposed. Heavy coffee drinkers in professional environments, particularly those in shift work, healthcare, or long-hours industries, tend to use caffeine instrumentally to manage fatigue rather than for pleasure. Once it becomes functional in that way, stopping becomes practically difficult as well as physiologically uncomfortable.

    People with anxiety disorders are in a particularly complicated position. Caffeine raises cortisol and can exacerbate anxiety symptoms, yet many anxious people are also heavy caffeine users. Withdrawal itself causes anxiety-like symptoms, which can make it hard to attribute what you’re feeling to caffeine removal. I’ve spoken to GPs who describe patients presenting with “mystery” headaches and fatigue that resolve when caffeine is gently tapered; the connection is often missed because nobody thinks to ask about it.

    If you’re already reading about how sedentary desk-based work affects cardiovascular health, it’s worth factoring caffeine into that picture too. Caffeine can raise blood pressure transiently, and people in high-stress, low-movement jobs are often the heaviest consumers.

    How to honestly assess your own intake

    The simplest test isn’t a blood panel or an app. Skip caffeine entirely for 48 hours and pay attention to what happens. If you develop a headache within 12 to 24 hours, feel noticeably foggy, struggle to concentrate, or feel irritable without an obvious cause, you are experiencing withdrawal. That is the clinical signal.

    A more structured approach is to track your daily intake for a week using a reliable reference, such as the caffeine content information published by UK brands and independently verified sources. Add up all sources: coffee, tea, energy drinks, pre-workout powders, some pain relief medications like Anadin Extra (which contain 65mg per tablet). You may be surprised by the total.

    If you decide you want to reduce, a gradual taper rather than abrupt cessation is the approach most consistently recommended in the literature. Cutting by roughly 10% every few days allows the brain’s adenosine receptor density to normalise without triggering severe withdrawal. Going cold turkey works for some people, but the headache can last three to five days and is genuinely unpleasant.

    None of this is an argument that caffeine is dangerous or that you need to quit. For most people, moderate intake is fine and carries some documented benefits, including reduced risk of type 2 diabetes and improved cognitive performance in the short term. The point is that dependence and harm are not the same thing. You can be dependent on something that does you no serious damage. But knowing you’re dependent, and understanding what that means physiologically, is useful information. A lot of UK adults are running on caffeine while believing they’re simply “not a morning person without coffee”. The research suggests something more specific is going on.

    If your sleep is suffering, it’s also worth considering how caffeine timing interacts with that. We’ve covered the science of sleep disruption in the UK context before, and caffeine’s half-life of roughly five to seven hours means a 4pm espresso is still active in your system well past midnight. And for anyone already thinking about supplements and micronutrient intake alongside their daily coffee habit, our piece on omega-3 gaps in British diets is a useful companion read, given the interaction between chronic inflammation and caffeine’s cortisol effects.

    The bottom line: caffeine dependence UK is not a niche clinical curiosity. It is a documented, pharmacologically grounded condition affecting a large share of the UK adult population. Understanding it honestly is the first step to managing it on your own terms.

    Frequently Asked Questions

    Is caffeine dependence a real medical diagnosis in the UK?

    Yes. Caffeine dependence is formally recognised under ICD-11, the World Health Organisation’s current international classification of diseases, which UK health services use. It has specific diagnostic criteria including tolerance, withdrawal symptoms, and difficulty controlling use.

    How much caffeine per day causes dependence?

    Research cited in peer-reviewed pharmacology literature suggests withdrawal can occur in regular users consuming as little as 100mg per day, roughly the amount in one strong cup of coffee. The risk increases with higher and more consistent daily intake.

    What are the withdrawal symptoms of caffeine and how long do they last?

    Common symptoms include headaches, fatigue, difficulty concentrating, low mood, and irritability. They typically begin 12 to 24 hours after the last caffeine dose, peak around 20 to 51 hours, and can last up to a week in some individuals.

The Latest